Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

ESMO 2023: Tarlatamab Primed To Take Big BiTE Out Of SCLC Market

Oct 20 2023

• By Kevin Grogan

Amgen

Related Content

Third-Line’s A Charm: Amgen Aims To Take A BiTE Out Of Pretreated SCLC

Aug 09 2022

Related Companies

Amgen, Inc.

Merck & Co., Inc.

Bristol Myers Squibb Company

Additional Topics

Clinical Trials Research & Development Strategy Cancer BioPharmaceutical ESMO

More from Anticancer

More from Therapy Areas

Twitter feed RSS feed RSS feed

About UsOpens in new window
Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us
Customer Service
Subscribe
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window